A comparison between p16-positive head and neck cancer of unknown primary (HPV-HNCUP) and oropharyngeal squamous cell carcinoma (HPV-OPSCC): are they the same disease?
Cancer of unknown primary
HPV-HNCUP
HPV-OPSCC
Head and neck cancer
Neck dissection
Oropharyngeal cancer
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
16
05
2023
accepted:
03
07
2023
medline:
2
11
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
The following study aimed to answer the question if HPV-HNCUP and HPV-OPSCC are the same disease. Propensity score matching (PSM) was used to compare the oncological outcomes of both groups, in particular the 5-year overall survival rate (OS), the 5-year disease specific survival rate (DSS) and the 5-year progression free survival rate (PFS). Firstly, between January 1st, 2007, and March 31st, 2020 a total of 131 patients were treated with HNCUP at our Department. Out of these, 21 patients with a confirmed positive p16 status were referred to surgery followed by adjuvant therapy. Secondly, between January 1st, 2000, and January 31st, 2017, a total of 1596 patients were treated with an OPSSC at our Department. Out of these, 126 patients with a confirmed positive p16 status were referred to surgery followed by adjuvant therapy. After PSM, 84 patients with HPV-OPSCC and 21 HPV-HNCUP remained in the study for further comparison. The OS was 63.5% (95% CI 39.4-87.6) for HPV-HNCUP and 88.9% (95% CI 90.4-100.0) for HPV-OPSCC patients and therefore, significantly lower for the first mentioned (p = 0.013). The DSS was also significantly impaired for HPV-HNCUP (71.0%, 95% CI 46.3-95.7), in comparison with HPV-OPSCC patients (95.5%, 95% CI 90.4-100.0; p = 0.002). The PFS for HPV-HNCUP patients was lower (75.6%, 95% CI 54.0-97.2) yet not significantly different to HPV-OPSCC (90.4%, 95% CI 83.5-97.3; p = 0.067). The results presented demonstrate a significant reduced OS and DSS for HPV-HNCUP patients. Accordingly, in our study HPV-HNCUP and HPV-OPSCC are two different entities with a different oncological outcome.
Identifiants
pubmed: 37505261
doi: 10.1007/s00405-023-08115-5
pii: 10.1007/s00405-023-08115-5
pmc: PMC10620243
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5489-5497Informations de copyright
© 2023. The Author(s).
Références
J Otolaryngol Head Neck Surg. 2017 Jun 10;46(1):45
pubmed: 28601094
Oral Oncol. 2012 Dec;48(12):1191-201
pubmed: 22841677
Oral Oncol. 2019 Jan;88:145-152
pubmed: 30616785
Cancer. 2009 Dec 15;115(24):5700-10
pubmed: 19691095
PLoS One. 2014 Nov 04;9(11):e110456
pubmed: 25369118
Int J Oncol. 2014 Jun;44(6):1799-805
pubmed: 24676623
Oral Oncol. 2020 Aug;107:104721
pubmed: 32361566
Int J Cancer. 2018 Apr 1;142(7):1361-1368
pubmed: 29159804
Int J Cancer. 2019 Sep 15;145(6):1465-1474
pubmed: 30698281
Anticancer Res. 2016 Feb;36(2):487-93
pubmed: 26851001
Eur J Cancer. 2017 Mar;74:73-81
pubmed: 28335889
Oral Dis. 2015 May;21(4):417-31
pubmed: 24962169
Arch Otolaryngol Head Neck Surg. 1991 Jun;117(6):601-5
pubmed: 2036180
J Clin Oncol. 2008 Feb 1;26(4):612-9
pubmed: 18235120
Otolaryngol Head Neck Surg. 2015 Nov;153(5):758-69
pubmed: 26124261
J Clin Oncol. 2015 Oct 10;33(29):3235-42
pubmed: 26351338
Head Neck. 2014 Dec;36(12):1677-84
pubmed: 24115269
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Laryngoscope. 2018 Jun;128(6):1379-1385
pubmed: 29086413
Int J Cancer. 2015 Apr 1;136(7):1494-503
pubmed: 24622970
ORL J Otorhinolaryngol Relat Spec. 2014;76(3):137-46
pubmed: 24993345
J Clin Oncol. 2020 Aug 1;38(22):2570-2596
pubmed: 32324430
Head Neck Oncol. 2010 Jun 29;2:15
pubmed: 20587061
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Oral Oncol. 2012 Nov;48(11):1178-84
pubmed: 22739067
Lancet Oncol. 2010 Aug;11(8):781-9
pubmed: 20451455
JAMA Otolaryngol Head Neck Surg. 2016 Mar;142(3):223-8
pubmed: 26769661
Clin Otolaryngol. 2017 Dec;42(6):1247-1251
pubmed: 28258624
CA Cancer J Clin. 2017 Jan;67(1):51-64
pubmed: 28076666
Cancer. 2016 Nov 15;122(22):3464-3471
pubmed: 27419843